New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies

Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic reaction The US FDA recently approved Xolair as the first and only medicine for children and adults with one or […]

Related Keywords

United States ,American ,Parag Mahanti ,Michael Meo ,Marlena Abdinoor ,America Julie Masow ,Jonathan Graham ,R Sharon Chinthrajah ,Angelika Jahreis ,Sloan Simpson ,Robert Wood ,Genentech ,National Institute Of Allergy ,Genentech Inc ,Drug Administration ,Seann Parker Center ,American Academy Of Allergy ,Roche Group ,Eudowood Division Of Allergy ,Public Health Impact Of Parent ,Consortium For Food Allergy Research Co ,Facebook ,Novartis ,Instagram ,Exchange Commission ,National Institutes Of Health ,Johns Hopkins Children Center ,Stanford School Of Medicine ,Novartis Pharmaceuticals Corporation ,Asthma Research ,Inspection Service ,Linkedin ,Development Unit Head ,National Institutes ,New England Journal ,Eudowood Division ,Johns Hopkins Children ,Associate Professor ,Stanford School ,Secondary Endpoints Results ,Pediatric Population ,Key Secondary ,Additional Secondary ,Adjunct Therapy ,Food Allergic Children ,National Institute ,Infectious Diseases ,Food Allergy Research ,Novartis Pharmaceuticals ,Important Safety ,Important Safety Information ,Food Allergies Among ,Public Health Impact ,Parent Reported Childhood Food Allergies ,Accessed November ,Food Equivalents ,Food Allergy ,Environmental Factors ,Accessed February ,